Novel curcumin extract from OmniActive Health Technologies shows high bioavailability in recent study
A recent study1 investigated the bioavailability of a proprietary curcumin formulation called Curcumin Ultra+ (OmniActive Health Technologies, based in Morristown, NJ), comparing it to 95% turmeric extract. In the randomized, double-blind, three treatment, crossover oral bioavailability study, 24 healthy volunteers were given either 250 mg of Curcuwin Ultra+, 500 mg of Curcuwin Ultra+, or 1,900 mg of the turmeric extract. Blood samples were collected at 4 hours and 0 hours before dosing, then 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, ands 24 hours after dosing. Researchers measured total curcuminoids as curcumin, demethoxycurcumin, bisdemethoxycurcumin, and tetrahydrocurcumin using a validated LC–MS/MS method.
Results showed that the curcumin extract achieved significantly higher maximum plasma concentrations and total system exposure for total curcuminoids compared to the turmeric extract. Researchers observed 101 and 100 times higher maximum plasma concentration for 250 mg and 500 mg of Curcuwin Ultra+, respectively, compared to the turmeric extract. Total systemic exposure from 0 to 6 hours was also 144 and 149 times higher for 250 mg and 500 mg of Curcuwin Ultra+, respectively, compared to the turmeric extract. Total systemic exposure from 0 to 12 hours was 99 and 113 times higher for 250 mg and 500 mg of Curcuwin Ultra+, respectively, compared to the turmeric extract. Additionally, the curcumin extract had 40% better absorption.
“OmniActive continues to champion innovation and invest in science for the betterment of human nutrition,” said Deshanie Rai, PhD, FACN, VP, global scientific and regulatory affairs at OmniActive, in a press release. “Having our data selected to be presented at the prestigious Experimental Biology meeting [in Philadelphia, PA] and accepted for publication in the well-respected peer-reviewed journal Advances in Therapy speaks to the strength and relevance of this new science.”
Kothaplly S et al. “Superior bioavailability of a novel curcumin formulation in healthy humans under fasting conditions.” Advances in Therapy, Published online ahead of print on March 16, 2022, https://doi.org/10.1007/s12325-022-02081-w